Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Final Guidance For Reporting Adverse Events Gets Serious On Definitions

This article was originally published in The Tan Sheet

Executive Summary

A report of emergency room treatment connected to use of a dietary supplement may not connote a serious adverse event, FDA says in the final guidance on the reporting and recordkeeping of AE information for supplements

You may also be interested in...

Robust Internal AER Systems Follow Supplement Lifecycle – Nature's Bounty Expert

Robust dietary supplement adverse event compliance systems can support faster identification of problems and improve products, says Nature’s Bounty Product Vigilance Manager Christina Romano. During a recent CRN webinar, she said distributors, retailers and researchers should be part of the reporting system.

FTC Shares Doubts About Supplements, Ad Claims In Its Consumer Library

FTC announces an addition to its library of consumer information with on supplements. It also notes online initiative by the Consortium for Health and Military Performance at the Uniformed Services University of the Health Sciences "mostly intended for the military community" but also relevant to other consumers.

Supplement Own-Labeler’s GMP Stumble Reveals AER Slip

FDA warns own-labelers ProSupps USA and Cape Fear Naturals about GMP violations, also pointing out ProSupps dropped the ball on submitting serious AERs to FDA and Cape Fear Naturals made drug claims including “improve blood pressure and cholesterol.”

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts